Chronic heart failure
Conditions
Interventions
experimental group:Transdermal topical use: Professor Zhang Lijing's experience prescription (Astragalus, Mai Dong and other confidential prescriptions) tincture transdermal external use
control group:Transdermal topical application of Professor Zhang Lijing's experience prescription tincture placebo
Sponsors
Dongzhimen Hospital Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Age= 18 years old and = 85 years old, gender is not limited; (2) meet the diagnostic criteria; (3) TCM dialectics is a patient with heart failure that conforms to the pattern of qi deficiency and blood stasis; (4) Voluntarily participate, understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Those who are in the acute stage of heart disease and whose condition is not controlled; (2) Patients with valvular heart disease, cardiomyopathy, coronary myobridge, aortic dissection, acute pericarditis, acute pericarditis, and cardiac insufficiency; (3) Patients with congenital heart disease; (4) Patients with uncontrolled grade 3 hypertension (systolic blood pressure = 180mmHg and/or diastolic blood pressure =110mmHg), severe cardiopulmonary insufficiency, severe arrhythmia, serious primary diseases such as liver, kidney and hematopoietic system, or serious diseases (such as tumors, etc.) and mental illness that affect their survival; (5) Patients with abnormal liver and kidney function indicators (ALT, AST, and Scr exceed the upper limit of the normal reference range by 1.5 times); (6) Patients with allergies, or allergies to multiple drugs and foods, or patients who are known to be allergic to the test drugs (including their components); (7) Those who have a pregnancy plan or pregnant or lactating women; (8) Patients with malignant tumors; (9) Patients with cerebrovascular or hematologic primary diseases; (10) Patients who have participated in other clinical trials in the past 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LVEF;liver function tests;hs-CRP;ECG;Myocardial injury markers;blood coagulation tests;NLR;Seattle Angina Scale;NT-proBNP;IL-6;Urinalysis;TCM Symptom Points; | — |
Countries
China
Contacts
Public ContactZHANG Lijing
Dongzhimen Hospital Beijing University of Chinese Medicine
Outcome results
None listed